<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ZOLEDRONIC ACID</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ZOLEDRONIC ACID</h1>

        <p><a href="../drugClass/PHP34620.html">BISPHOSPHONATES</a></p>

      <nav>
        <ul class="nav nav-list">

          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">




      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid&#8212;toxicity in <i>animal</i> studies.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Caution in severe hepatic impairment&#8212;limited information available.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>In advanced malignancies involving bone, if eGFR 50&#8211;60&#8239;mL/minute/1.73&#8239;m<sup>2 </sup>reduce dose to 3.5&#8239;mg every 3&#8211;4 weeks; if eGFR 40&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup> reduce dose to 3.3&#8239;mg every 3&#8211;4 weeks; if eGFR 30&#8211;40&#8239;mL/minute/1.73&#8239;m<sup>2</sup> reduce dose to 3&#8239;mg every 3&#8211;4 weeks; if renal function deteriorates in patients with bone metastases, withhold dose until serum creatinine returns to within 10% of baseline value.</p>
            </section>
        
            <section class="generalInformation">
              <p>Avoid in tumour-induced hypercalcaemia if serum creatinine above 400&#8239;micromol/litre.</p><p>Avoid in advanced malignancies involving bone if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup> (or if serum creatinine greater than 265&#8239;micromol/litre).</p><p>Avoid in Paget&#8217;s disease, treatment of postmenopausal osteoporosis and osteoporosis in men if eGFR less than 35&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Anaemia, arthralgia, atrial fibrillation, bone pain, conjunctivitis, dizziness, fever, gastro-intestinal disturbances, headache, hypophosphataemia, influenza- like symptoms, myalgia, renal impairment, rigors,
              </p>
              <p>
                <strong>uncommon:</strong> Angioedema, anorexia, anxiety, asthenia, blurred vision, chest pain, cough, dry mouth, dyspnoea, haematuria, hypersensitivity reactions, hypertension, hypokalaemia, hypomagnesaemia, hypotension, injection-site reactions, lethargy, leucopenia, muscle cramps, paraesthesia, peripheral oedema, proteinuria, pruritus, rash, sleep disturbance, stomatitis, sweating, taste disturbance, thrombocytopenia, tremor, urinary frequency, weight gain,
              </p>
              <p>
                <strong>rare:</strong> Acute renal failure, atypical femoral fractures, bradycardia, confusion, hyperkalaemia, hypernatraemia, osteonecrosis of the jaw, pancytopenia,
              </p>
              <p>
                <strong>veryRare:</strong> Episcleritis, uveitis,
              </p>
        
        
            <section class="advice">
                <h3>Renal function</h3>
              <p>Renal impairment and renal failure have been reported; ensure patient is hydrated before each dose and assess renal function.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>For <i>intravenous infusion</i> (<i>Zometa</i>
            <tm tmtype="reg"/>), give intermittently in Glucose 5% <i>or</i> Sodium chloride 0.9%; dilute requisite dose according to product literature; infuse over at least 15 minutes; administer as a single intravenous solution in a separate infusion line.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="patientResources">
              <p>A patient reminder card should be provided (risk of osteonecrosis of the jaw).</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Atypical femoral fractures
          </li>
          <li>
            cardiac disease (avoid fluid overload)
          </li>
          <li>
            concomitant medicines that affect renal function
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Contra-indicated in women of child-bearing potential.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Correct disturbances of calcium metabolism (e.g. vitamin D deficiency, hypocalcaemia) before starting. Monitor serum electrolytes, calcium, phosphate and magnesium.</p><p>Monitor renal function in patients at risk, such as those with pre-existing renal impairment, those of advanced age, those taking concomitant nephrotoxic drugs or diuretics, or those who are dehydrated.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ZOLEDRONIC ACID</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP74902"><a href="../medicinalForm/PHP74902.html" data-target="#PHP74902" data-action="load">Infusion</a></div>
            <div id="PHP74896"><a href="../medicinalForm/PHP74896.html" data-target="#PHP74896" data-action="load">Solution for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
